Prescribing decisions affected by student interaction with marketers

Article

Medical trainees who spend more time with pharmaceutical marketing representatives are less likely to make evidence-based choices when prescribing, according to a study recently published in JAMA Internal Medicine.

Medical trainees who spend more time with pharmaceutical marketing representatives are less likely to make evidence-based choices when prescribing, according to a study recently published in JAMA Internal Medicine.

Researchers surveyed a randomly selected, nationally representative sample of first- and fourth-year medical students, as well as third-year residents.

Study: 90 percent of health-related Wikipedia articles contain errors

“All trainees were asked how often they used different educational resources to learn about prescription drugs. Among fourth-year students and residents, we posed a series of multiple choice knowledge questions asking about the appropriate initial therapy for clinical scenarios involving patients with diabetes, hyperlipidemia, hypertension, and difficulty sleeping,” the study’s authors say.

Participants were also asked about frequency in the past six months of interactions with the pharmaceutical industry, their expected frequency of interactions in their careers, and their attitudes about such interactions. Researchers used the survey answers to build an industry relations index assessing each trainee’s level of acceptance of pharmaceutical promotion.

The study found that 48 percent to 90 percent of fourth-year students and residents accurately identified evidence-based prescribing choices. According to researchers, a 10-point higher industry relations index was associated with 15 percent lower odds of selecting an evidence-based prescribing choice. The study also found there was a significant association between the industry relations index and greater odds of choosing to prescribe brand-name drugs.

The study also found that the 1601 students and 735 residents who participated reported common use of unfiltered sources of drug information such as Google (74.2 percent to 88.9 percent) and Wikipedia (45.2 percent to 84.5 percent).

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
© 2025 MJH Life Sciences

All rights reserved.